CXCL12 and angioimmunoblastic T-cell lymphoma: Preliminary results of a phase II study showed that tipifarnib, a selective inhibitor of the farnesyltransferase enzyme which aids CXCL12 secretion, elicited a 56.3% ORR and 28.1% CR rate in AITL (n = 32).